Preliminary Evaluation of Three-Dimensional Primary Human Hepatocyte Culture System for Assay of Drug-Metabolizing Enzyme-Inducing Potential.

Drug-induced liver injury (DILI) is a common reason for withdrawal of candidate drugs from clinical trials, or of approved drugs from the market. DILI may be induced not only by intact parental drugs, but also by metabolites or intermediates, and therefore should be evaluated in the enzyme-induced state. Here, we present a protocol for assay of drug-metabolizing enzyme-inducing potential using three-dimensional (3D) primary cultures of human hepatocytes (hepatocyte spheroids). Hepatocyte spheroids could be used up to 21 d after seeding (pre-culture for 7 d and exposure to inducer for up to 14 d), based on preliminary evaluation of basal activities of CYP subtypes and mRNA expression of the corresponding transcription factor and xenobiotic receptors (aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR) and pregnane X receptor (PXR)). After 2 d exposure of hepatocyte spheroids to omeprazole, phenobarbital and rifampicin (typical inducers of CYP1A2, 2B6 and 3A4, respectively), CYP1A2, 2B6 and 3A4 mRNA expression levels were significantly increased. The mRNA induction of CYP2B6 remained reasonably stable between days 2 and 14 of exposure to inducers, while induction of both CYP1A2 and 3A4 continued to increase up to day 14. These enzyme activities were all significantly increased compared with the control until day 14. Our findings indicate that our 3D hepatocyte spheroids system would be especially suitable for long-term testing of enzyme activity induction by drugs, either to predict or to verify clinical events.

[1]  G. Prasad,et al.  Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report. , 2003, Transplantation proceedings.

[2]  H. Arakawa,et al.  Evaluation of human hepatocytes cultured by three-dimensional spheroid systems for drug metabolism. , 2014, Drug metabolism and pharmacokinetics.

[3]  R Ohlsson,et al.  Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Obach,et al.  Cytochrome P450 3A4 mRNA Is a More Reliable Marker than CYP3A4 Activity for Detecting Pregnane X Receptor-Activated Induction of Drug-Metabolizing Enzymes , 2010, Drug Metabolism and Disposition.

[5]  L. Benet,et al.  Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction , 1992, Clinical pharmacology and therapeutics.

[6]  H. Arakawa,et al.  Utility of human hepatocyte spheroids for evaluation of hepatotoxicity , 2015 .

[7]  P. Neuvonen,et al.  Rifampin drastically reduces plasma concentrations and effects of oral midazolam , 1996, Clinical pharmacology and therapeutics.

[8]  E. Glover,et al.  Species differences in responsiveness to 1,4-bis[2-(3,5-dichloropyridyloxy)]-benzene, a potent phenobarbital-like inducer of microsomal monooxygenase activity. , 1981, Molecular pharmacology.

[9]  M. Shimizu,et al.  Evaluation of 23 Lots of Commercially Available Cryopreserved Hepatocytes for Induction Assays of Human Cytochromes P450 , 2014, Drug Metabolism and Disposition.

[10]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[11]  Tommy B Andersson,et al.  The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human , 2012, Expert opinion on drug metabolism & toxicology.

[12]  E L LeCluyse,et al.  Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. , 2001, Chemico-biological interactions.

[13]  Taosheng Chen,et al.  Pregnane X receptor and drug-induced liver injury , 2014, Expert opinion on drug metabolism & toxicology.

[14]  M. T. Donato,et al.  Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. , 2001, Archives of biochemistry and biophysics.

[15]  J. Lehmann,et al.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.

[16]  Jie Lu,et al.  Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co–therapy , 2013, Nature Medicine.

[17]  S. Wolfe,et al.  Timing of new black box warnings and withdrawals for prescription medications. , 2002, JAMA.

[18]  Stephen S Ferguson,et al.  A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes. , 2012, Journal of pharmaceutical sciences.

[19]  Guideline on the Investigation of Drug Interactions , 2010 .

[20]  R. Fisher,et al.  Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[21]  Shu-Feng Zhou,et al.  Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2 , 2009, The AAPS Journal.

[22]  Paavo Honkakoski,et al.  The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene* , 1999, The Journal of Biological Chemistry.

[23]  Q. Meng.  Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity , 2010, Expert opinion on drug metabolism & toxicology.